Disclaimer
The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.
We are a pioneer in treating drug-resistant fluid overload, a serious and frequent clinical complication in patients with liver disease and heart failure.
alfapump® and DSR® are Sequana Medical’s proprietary approaches that work with the body to remove this excess fluid. While DSR is still in development, alfapump® is delivering clinical and quality of life benefits for patients and reducing costs for healthcare systems. We are listed on Euronext Brussels, headquartered in Ghent, Belgium and also have offices in Zurich, Switzerland.
We embrace diversity and inclusion. You will have the opportunity to work with outstanding business teams and contribute to the success of the company. We strive to provide all our employees with the means to develop their skills and experiences, at every level.
Do you have a passion for the medical technology sector, combined with a strong drive for strategic communication and stakeholder engagement?
We are looking for a Director Investor Relations & Corporate Communications to join our leadership team.
In this role, you will be responsible for ensuring accurate, timely, and compliant communication of the company’s strategic priorities, operational progress, and financial performance to external stakeholders. You will lead all investor relations and corporate communications activities, including digital platforms, and play a key role in strengthening the company’s profile in the financial markets and broader healthcare ecosystem.
You will collaborate closely with the CEO and senior leadership to develop investor-facing materials, manage media engagement, and oversee regulatory-compliant disclosure. The role combines strategic scope with hands-on execution and involves regular interaction with analysts, journalists, and shareholders.
We’re looking for a confident, structured communicator with a scientific background, an understanding of capital markets, and the ability to engage effectively with stakeholders at all levels.
Join a company at the forefront of medical innovation and contribute to how we communicate our purpose, progress, and priorities to the world!
Does this opportunity sound exciting? Join our dynamic team in Ghent!
Send your CV and full application (in Dutch or English) to careers@sequanamedical.com.
We look forward to hearing from you!
[2] Quality of life as defined by subjective physical health (assessed by SF-36 PCS) and ascites symptoms (assessed by Ascites Q)
[1] POSEIDON study results in SSED (PMA P230044, FDA approval letter on file) – 100% median reduction in number of therapeutic paracentesis per month in Pivotal Cohort
GlobalData NASH Epidemiology Forecast to 2026
Testani JM, Hanberg JS, Cheng S, et al. Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure. Circulation Heart failure. 2016;9(1):e002370. doi:10.1161/CIRCHEARTFAILURE.115.002370
Kilgore et al. (2017); Ambrosy et al. (2014)
Ginès et al. (2004) (déclarant que l’ascite réfractaire apparaît chez 5 à 10% des patients souffrant d’ascite)
Runyon et al. (2009)
World Health Organization International Agency for Research on Cancer 2018 (website) (estimated number of new breast and ovarian cases in 2018 (crude rate))
Ayantunde et al. (2006)
Benjamin et al. (2013)
Costanzo et al. (2007)
Kilgore et al. (2017)
Estes et al. (2018)
European Association for the Study of the Liver. EASL clinical practice guideliones on the management of ascites, spontane bacterial peritonitis, and hepatorenal syndrome in cirrhosis. Journel of Hepatology. 2010 vol. 53. 397-417. p. 402
U.S. Centers for Disease Control and Prevention, Health, United States 2016, Chartbook on Long-term trends in Health, Table 20 (web site)
United States
Stay on sequanamedical.com
Europe
Go to alfapump.com